Jennifer Woyach, MD, discusses the benefit of a combination therapy with ibrutinib for patients with chronic lymphocytic leukemia (CLL).
Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefit of a combination therapy with ibrutinib for patients with chronic lymphocytic leukemia (CLL).
Woyach says a physician might decide to use a combination therapy with ibrutinib because of the drug’s side effect of peripheral lymphocytosis. However, researchers do not know if the peripheral lymphocytosis is detrimental to the patient’s health.
Since most of the responses that are seen in the relapse setting with ibrutinib are partial responses, physicians may want to use other therapies in combination with ibrutinib to get a complete response, Woyach says.
Woyach believes the most attractive agents to combine with ibrutinib are the ones that are well tolerated as most patients with CLL are older or patients who have had chemo-immunotherapy previously.
Clinical Pearls
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More